Lebrikizumab

ATC D11AH10 · 10 markets · 15 records

Lebrikizumab 10 markets · 15 records Forms

US 2 records · 1 strengths

250 mg/2 mLinjectionEBGLYSS also in GB·SG

GB 2 records · 1 strengths

250 mg/2 mLinjectionEbglyss 250mg/2ml solution for injection pre-filled pens+1Ebglyss 250mg/2ml solution for injection pre-filled syringes also in US·SG

CA 2 records · 1 strengths

125 mg/1 mLliquidEBGLYSS

AU 2 records · 2 strengths

125 mg/mLinjectionEBGLYSS lebrikizumab 250 mg/2 mL solution for injection autoinjector (pre-filled pen) unknown

Records without a stated strength · 1 EBGLYSS

ES 2 records · 1 strengths

250 mginjectionEBGLYSS PRECARGADA

SG 1 records · 1 strengths

250 mg/2 mLinjectionEBGLYSS SOLUTION FOR INJECTION IN PRE-FILLED PEN 250MG/2ML also in US·GB

MX 1 records · 1 strengths

Records without a stated strength · 1 EBGLYSS

TW 1 records · 1 strengths

Records without a stated strength · 1 EBGLYSS、異可適注射劑

HK 1 records · 1 strengths

Records without a stated strength · 1 EBGLYSS SOLUTION FOR INJECTION IN PRE-FILLED PEN 250MG/2ML

EU 1 records · 1 strengths

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

Records without a stated strength · 1 EBGLYSS

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.

A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.